Acta Pharmaceutica, Vol. 68 No. 4, 2018.
Izvorni znanstveni članak
https://doi.org/10.2478/acph-2018-0040
Immunomodulatory effects of tigecycline in Balb/c mice
SHADA Y. ELHAYEK
; Department of Biopharmaceutics and Clinical Pharmacy School of Pharmacy, University of Jordan, Amman, Jordan
MOHAMMAD A. FARARJEH
; Al-Quds medical labs, AL-Zarqa, Jordan
AREEJ M. ASSAF
; Department of Biopharmaceutics and Clinical Pharmacy School of Pharmacy, University of Jordan, Amman, Jordan
EMAN ABU RISH
; Department of Biopharmaceutics and Clinical Pharmacy School of Pharmacy, University of Jordan, Amman, Jordan
YASSER BUSTANJI
; Department of Biopharmaceutics and Clinical Pharmacy School of Pharmacy, University of Jordan, Amman, Jordan; Hamdi Mango Center for Scientific Research, Amman, Jordan
Sažetak
Tigecycline is a glycylcycline antibiotic approved by the FDA for the treatment of complicated infections. Despite its effectiveness, the FDA announced a warning of increasing mortality associated with its use. There is, however, no clear explanation for this side effect. Previous reports found a possible effect of tigecycline on leukocyte proliferation and proinflammatory cytokine release. We therefore investigated the effect of tigecycline on the immune components and response in Balb/c mice in vivo and in vitro. It was found that tigecycline enhanced lymphocyte proliferation and significantly increased cellular infiltration within the footpad, as based on DTH testing, but reduced the hemagglutination titer. In splenocyte cultures, tigecycline suppressed splenocyte proliferation with IC50 3–5 mol L–1, significantly increased IL-2 secretion and reduced IL-17 secretion in a dose dependent mode. In conclusion, tigecycline is safe at therapeutic and sub-therapeutic doses, but it could still have an immunomodulatory effect at higher doses. Use of higher doses of tigecycline requires further investigation.
Ključne riječi
tigecycline; immunomodulation; Balb/c mice; biochemical effect
Hrčak ID:
203274
URI
Datum izdavanja:
31.12.2018.
Posjeta: 978 *